与程序性细胞死亡1蛋白抑制剂纳武单抗相关的大疱性类天疱疮。 - Suppr

Suppr

超能文献

Bullous pemphigoid associated with nivolumab, a programmed cell death 1 protein inhibitor.

作者信息

Kwon C W, Land A S, Smoller B R, Scott G, Beck L A, Mercurio M G

机构信息

Department of Dermatology, University of Rochester Medical Center, Rochester, NY, USA.

Department of Pathology, University of Rochester Medical Center, Rochester, NY, USA.

出版信息

J Eur Acad Dermatol Venereol. 2017 Aug;31(8):e349-e350. doi: 10.1111/jdv.14143. Epub 2017 Mar 3.

DOI:10.1111/jdv.14143

PMID:28129461

Abstract

摘要

相似文献

Bullous pemphigoid associated with nivolumab, a programmed cell death 1 protein inhibitor.

J Eur Acad Dermatol Venereol. 2017 Aug;31(8):e349-e350. doi: 10.1111/jdv.14143. Epub 2017 Mar 3.

Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.

Expert Opin Drug Saf. 2019 Jul;18(7):623-633. doi: 10.1080/14740338.2019.1619693. Epub 2019 May 22.

A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management.

Oncologist. 2018 Oct;23(10):1119-1126. doi: 10.1634/theoncologist.2018-0128. Epub 2018 Jul 17.

Bullous pemphigoid developing upon immune checkpoint inhibition with nivolumab.

Eur J Dermatol. 2019 Aug 1;29(4):448-449. doi: 10.1684/ejd.2019.3614.

Nivolumab-induced bullous pemphigoid after radiotherapy and abscopal effect.

Australas J Dermatol. 2019 Aug;60(3):e235-e236. doi: 10.1111/ajd.12987. Epub 2018 Dec 27.

Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy.

JAMA Dermatol. 2018 Sep 1;154(9):1057-1061. doi: 10.1001/jamadermatol.2018.1912.

Nivolumab-associated bullous pemphigoid reactions involving multiple epitopes.

Eur J Dermatol. 2019 Oct 1;29(5):552-554. doi: 10.1684/ejd.2019.3619.

Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.

J Am Acad Dermatol. 2018 Dec;79(6):1081-1088. doi: 10.1016/j.jaad.2018.07.008. Epub 2018 Jul 17.

Bullous pemphigoid induced by ipilimumab in a patient with metastatic malignant melanoma after unsuccessful treatment with nivolumab.

J Dermatol. 2018 Jan;45(1):e21-e22. doi: 10.1111/1346-8138.14043. Epub 2017 Sep 25.

Detection of IgG antibodies to BP180 NC16a and C-terminal domains and LAD-1 in nivolumab-associated bullous pemphigoid.

Eur J Dermatol. 2019 Oct 1;29(5):554-555. doi: 10.1684/ejd.2019.3618.

引用本文的文献

Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies.

Cancers (Basel). 2023 Jun 9;15(12):3126. doi: 10.3390/cancers15123126.

Front Immunol. 2023 Jan 26;14:1122430. doi: 10.3389/fimmu.2023.1122430. eCollection 2023.

A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors.

Cancers (Basel). 2022 Nov 5;14(21):5451. doi: 10.3390/cancers14215451.

Bullous Pemphigoid in Patients Receiving Immune-Checkpoint Inhibitors and Psoriatic Patients-Focus on Clinical and Histopathological Variation.

Dermatopathology (Basel). 2022 Mar 18;9(1):60-81. doi: 10.3390/dermatopathology9010010.

Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors.

Support Care Cancer. 2020 Dec;28(12):6119-6128. doi: 10.1007/s00520-020-05706-4. Epub 2020 Aug 27.

Nivolumab-Induced Bullous Pemphigoid Managed without Drug Withdrawal.

Indian J Dermatol. 2020 May-Jun;65(3):214-216. doi: 10.4103/ijd.IJD_321_18.

Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.

J Am Acad Dermatol. 2020 Oct;83(4):1130-1143. doi: 10.1016/j.jaad.2020.04.105. Epub 2020 Apr 29.

Recurrence of Pemphigus Vulgaris Under Nivolumab Therapy.

Front Med (Lausanne). 2019 Nov 12;6:262. doi: 10.3389/fmed.2019.00262. eCollection 2019.

Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature.

Front Med (Lausanne). 2018 Sep 27;5:268. doi: 10.3389/fmed.2018.00268. eCollection 2018.

Oncologist. 2018 Oct;23(10):1119-1126. doi: 10.1634/theoncologist.2018-0128. Epub 2018 Jul 17.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验